FutureWiseResearch: Global Market Research Reports, USA, UK

Overview

Adoptive Cell Therapy for Cancer Treatment Market Overview:

According to FutureWise analysis, the market for Adoptive Cell Therapy for Cancer Treatment is expected to grow at a CAGR of 21.22% over the forecast period of 2023-2031.

Adoptive cell therapy, also called cellular immunotherapy, is a treatment that uses the cells of the immune system to eliminate cancer. The primary goal of ACT is to develop new ways to generate immune cells specifically targeted to fight cancer. Adoptive cell therapy (ACT) is a rapidly growing anti-cancer strategy that has shown assurance in treating various cancer types. ACT can be classified into three different types with each mechanism of action, including tumor-infiltrating lymphocytes (TILs), genetically engineered immune cells, and dendritic cells (DCs) vaccines. With the advancement of cell culture and genetic engineering techniques, ACT has been used in clinics to treat malignant hematological diseases, and many new ACT-based regimens are in different stages of clinical trials. Two main types of cells used in adoptive cell therapy are T cells and natural killer (NK) cells.

There are two types of T-cell transfer therapy: TIL (tumor-infiltrating lymphocytes) therapy and CAR T-cell therapy. Both involve collecting own immune cells, growing a large number of these cells in the lab, and then giving the cells back through a needle in the vein. The process of developing T cells in the lab may take 2 to 8 weeks. During this period, an individual may undergo chemotherapy and radiation therapy to eliminate other immune cells. The Reduction of immune cells helps the cultured T cells to be more efficient. After these treatments, the T cells cultivated in the laboratory will be delivered through intravenous infusion.

FutureWise Market Research has published a report that provides an insightful adoptive cell therapy for cancer treatment market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, adoptive cell therapy for cancer treatment market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

Major players included in the Adoptive Cell Therapy for Cancer Treatment Market:

Roche
Amgen
Janssen
Bristol-Myers Squibb
GlaxoSmithKline
Merck
Eli Lilly
Genentech

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Adoptive Cell Therapy for Cancer Treatment Market:

In February 2022, Innovent Biologics, Inc., a world-class biopharmaceutical company, together with IASO Biotherapeutics, a clinical-stage biopharmaceutical company, jointly announced that the U.S. FDA Office of Orphan Products Development (OOPD) had formally granted Orphan Drug Designation (ODD) to company’s co-developed fully-human B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell therapy. The therapy is intended to treat patients with relapsed or refractory multiple myeloma.
In November 2021, Laurus Labs, a pharmaceutical and biotechnology company based in India, signed an agreement to invest in Immunoadoptive Cell Therapy (ImmunoACT), an IIT-Bombay incubated company that's developing an indigenous CAR T-cell therapy for curing specific types of blood cancers. The Laurus Labs will acquire a 26.62% stake (fully diluted basis) in ImmunoACT for a cash consideration of approximately ?46 crore (U.S. $ 460 million).

The growing incidence of cancer, especially in hematological malignancies and solid tumors, serves as a significant driver for the adoption of Adoptive Cell Therapy (ACT). As cancer rates continue to increase globally, the efficacy of ACT in targeting and treating these cancer types is increasingly acknowledged. This fuels the demand for innovative therapies that offer better outcomes, leading to growing investment in the development of ACT as a potent weapon in the fight against cancer. Moreover, key players use various inorganic strategies, including fundraising, mergers, and acquisitions, to ensure the necessary capital and resources for R&D, which are expected to drive the growth of adoptive cell therapy for the cancer treatment market during the forecast period. These strategies are desired to increase market growth by enabling the advancement of innovative therapies, expanding production capacities, and expanding the reach of these therapies to a vast patient population. For instance, in April 2021, Arcellx, a privately held clinical-stage biopharmaceutical company, revealed that it raised US$ 115 million in Series C financing to advance its adaptive and controllable cell therapies pipeline. Furthermore, the shift into the new era of cell-based individualized therapeutics is expected to impede market growth. Challenges such as high treatment costs, complex manufacturing practices, and the need for skilled professionals may limit the accessibility of these advanced therapies to a broader patient population. Additionally, the regulatory standards and safety concerns demand stringent management, potentially slowing down the integration of these innovative approaches into conventional cancer therapy, thus increasing hurdles to widespread adoption further hindering the market growth.

Adoptive Cell Therapy for Cancer Treatment Market Segmentation:

By Type

Surgery
Chemotherapy
Radiotherapy

By Application

Autologous adoptive T cell therapy
Allogeneic Adoptive T cell therapy

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. This is attributed to a rising prevalence of cancer cases, growing demand for ideal therapeutics, established research & commercialization base, and key players focusing on growth strategies and product approvals for adoptive cell therapy, which are anticipated to propel the market growth in the United States. For instance, in January 2022, Sana Biotechnology Inc., a company focused on developing and providing engineered cells as therapeutics agents, announced that the company entered into a partnership with the NCI (National Cancer Institute), an institute of the National Institution of Health (NIH), for worldwide exclusive commercial rights to the NIH's CD22 chimeric antigen receptor (CAR) with a fully-human binder for use in specific vivo gene therapy and ex-vivo allogeneic CAR T application for B-cell malignancies. These above-mentioned factors are further driving the market growth over the projection period in the area.

Competitive Landscape:

Tier 1 players-established companies in the market with a major market share
Tier 2 players
Emerging players which are growing rapidly
New Entrants

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the Adoptive Cell Therapy for Cancer Treatment Market By Product Type, By Application and By Region.
To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customization Mobility Care offered are free of charge with purchase of any license of the report
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

1. Market Introduction
- 1. Objectives of the Study
  2. Market Definition
  3. Market Scope
  3.1 . Years Considered for the Study
  3.2 . Market Covered
  4. Currency
  5. Limitations
  6. Stakeholders
2. Research Methodology
- 1. Research Data
  1.1 . Secondary Data
  1.1.1 . Key Data from Secondary Sources
  1.2 . Primary Data
  1.2.1. Key Data from Primary Sources
  2. Market Size Estimation
  3. Market Breakdown and Data Triangulation
  4. Assumptions for the Study
3. Executive Summary
- 1. Market Outlook
  2. Segment Outlook
  3. Competitive Insights
4. Adoptive Cell Therapy for Cancer Treatment Market Variables, Trends and Scope
- 1. Market Lineage Outlook
  2. Penetration and Growth Prospect Mapping
  3. Industry Value Chain Analysis
  4. Cost Analysis Breakdown
  5. Type Overview
  6. Regulatory Framework
  6.1. Reimbursement Framework
  6.2. Standards and Compliances
5. Market Overview
- 1. Market Dynamics
  1.1. Market Driver Analysis
  1.1.1. Increasing focus of Adoptive Cell Therapy for Cancer Treatment Market Companies on Brand Protection
  1.1.2. Untapped Opportunities in Emerging Regions
  1.2. Market Restraint Analysis
  1.2.1. High Cost Associated with Implementation of Predictive Analysis
  1.3. Industry Challenges
  1.3.1. Presence of Ambiguous Regulatory Framework
6. Adoptive Cell Therapy for Cancer Treatment Market Analysis Tools
- 1. Industry Analysis - Porter’s
  1.1. Supplier Power
  1.2. Buyer Power
  1.3. Substitution Threat
  1.4. Threat from New Entrants
  1.5. Competitive Rivalry
  2. Pestel Analysis
  2.1. Political Landscape
  2.2. Environmental Landscape
  2.3. Social Landscape
  2.4. Type Landscape
  2.5. Legal Landscape
  3. Major Deals And Strategic Alliances Analysis
  3.1. Joint Ventures
  3.2. Mergers and Acquisitions
  3.3. Licensing and Partnership
  3.4. Type Collaborations
  3.5. Strategic Divestments
  4. Market Entry Strategies
  5. Case Studies
7. Adoptive Cell Therapy for Cancer Treatment Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Surgery
  2. Chemotherapy
  3. Radiotherapy
8. Adoptive Cell Therapy for Cancer Treatment Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Autologous adoptive T cell therapy
  2. Allogeneic Adoptive T cell therapy
9. North America Adoptive Cell Therapy for Cancer Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. U.S.A
  2.2. Canada
  2.3. Mexico
  3. Market Size (USD Million) Forecast for North America 2023-2031
10. Latin America Adoptive Cell Therapy for Cancer Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Brazil
  2.2. Venezuela
  2.3. Argentina
  2.4. Rest of Latin America
  3. Market Size (USD Million) Forecast for Latin America 2023-2031
11. Europe Adoptive Cell Therapy for Cancer Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Germany
  2.2. U.K
  2.3. France
  2.4. Italy
  2.5. Spain
  2.6. Russia
  2.7. Poland
  2.8. Rest of Europe
  3. Market Size (USD Million) Forecast for Europe 2023-2031
12. Asia Pacific Adoptive Cell Therapy for Cancer Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Japan
  2.2. China
  2.3. India
  2.4. Australia and New Zealand
  2.5. ASEAN
  2.6. Rest of Asia Pacific
  3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031
13. Middle East and Africa Adoptive Cell Therapy for Cancer Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Saudi Arabia
  2.2. UAE
  2.3. South Africa
  2.4. Egypt
  3. Market Size (USD Million) Forecast for MEA 2023-2031
14. Market Share Analysis and Competitive Landscape
- 1. Global Landscape - Key Players, Revenue and Presence
  2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
  3. Global Emerging Companies
  4. North America - Market Share Analysis and Key Regional Players
  5. Europe - Market Share Analysis and Key Regional Players
  6. Asia Pacific - Market Share Analysis and Key Regional Players
  7. Global Key Player - Growth Matrix
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
- 1. Roche
  1.1. Company Overview
  1.2. Product Portfolio
  1.3. SWOT Analysis
  1.4. Financial Overview
  1.5. Strategic Overview
  2. Amgen
  2.1. Company Overview
  2.2. Product Portfolio
  2.3. SWOT Analysis
  2.4. Financial Overview
  2.5. Strategic Overview
  3. Janssen
  3.1. Company Overview
  3.2. Product Portfolio
  3.3. SWOT Analysis
  3.4. Financial Overview
  3.5. Strategic Overview
  4. Bristol-Myers Squibb
  4.1. Company Overview
  4.2. Product Portfolio
  4.3. SWOT Analysis
  4.4. Financial Overview
  4.5. Strategic Overview
  5. GlaxoSmithKline
  5.1. Company Overview
  5.2. Product Portfolio
  5.3. SWOT Analysis
  5.4. Financial Overview
  5.5. Strategic Overview
  6. Merck
  6.1. Company Overview
  6.2. Product Portfolio
  6.3. SWOT Analysis
  6.4. Financial Overview
  6.5. Strategic Overview
  7. Eli Lilly
  7.1. Company Overview
  7.2. Product Portfolio
  7.3. SWOT Analysis
  7.4. Financial Overview
  7.5. Strategic Overview
  8. Genentech
  8.1. Company Overview
  8.2. Product Portfolio
  8.3. SWOT Analysis
  8.4. Financial Overview
  8.5. Strategic Overview
16. Pre and Post COVID-19 Impact
- 1. Positive influence on the healthcare industry
  2. The financial disruption of the manufacturing sector
  3. Impact of COVID-19 on emerging companies
  4. Significant mandates in the healthcare regulations initiated by
  administrations
  5. The overall economic slowdown of the developing and developed nations
17. FutureWise SME Key Takeaway Points for Client

Data Pack license: Data Pack license: $1250

Single user license: Single user license: $2850

Multi user license: Multi user license: $3850

Corporate license: Corporate license: $5000

Ask for Discount

Buy Now

Customize This Report

Partner

Report Overview

Table of Contents

List of Tables

List of figures

Overview

Table of Contents

Report Overview

Table of Contents

List of Tables

List of figures

Need Assistance

What you get

What's included

Our Clients